IONCTURA
iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes.... Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology.
IONCTURA
Industry:
Biotechnology Health Care Medical Device
Founded:
2017-06-01
Address:
Genève, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.ionctura.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
22.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Apache Global Site Tag
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Investors List
M Ventures
M Ventures investment in Series A - iOnctura
Inkef
Inkef investment in Series A - iOnctura
3B Future Health Fund
3B Future Health Fund investment in Series A - iOnctura
VI Partners
VI Partners investment in Series A - iOnctura
Schroder Adveq
Schroder Adveq investment in Series A - iOnctura
Schroder Adveq
Schroder Adveq investment in Series A - iOnctura
VI Partners
VI Partners investment in Series A - iOnctura
M Ventures
M Ventures investment in Series A - iOnctura
Inkef
Inkef investment in Series A - iOnctura
M Ventures
M Ventures investment in Seed Round - iOnctura
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-05 | iOnctura Strengthens Management With Appointment of Sean A. MacDonald as Chief Business Officer |
Official Site Inspections
http://www.ionctura.com Semrush global rank: 7.87 M Semrush visits lastest month: 420
- Host name: a6eac11e2686be3c9.awsglobalaccelerator.com
- IP address: 15.197.230.14
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "iOnctura"
About - iOnctura
Prior to founding iOnctura he has held various positions in project management and project leadership spanning early discovery up to commercial products and dealing with both biologics …See details»
iOnctura - Crunchbase Company Profile & Funding
Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical …See details»
iOnctura strengthens leadership with appointments of Chief …
Mar 17, 2025 iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces the appointments of Elizabeth Holt as Chief Business …See details»
iOnctura - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
iOnctura Company Profile - Office Locations, Competitors, …
IOnctura is a company that develops bio-molecules intended for the treatment of cancer and fibrosis. Its bio-molecules include novel therapeutics that modulate key culprits of …See details»
Our pipeline - iOnctura
Contact. iOnctura B.V. Gustav Mahlerplein 102 1082 MA Amsterdam The Netherlands iOnctura SA Campus Biotech Avenue de Sécheron 15 1202 Geneva SwitzerlandSee details»
iOnctura strengthens leadership with appointments of Chief …
6 days ago /PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces the appointments of...See details»
iOnctura strengthens leadership with appointments of Chief …
6 days ago Geneva, Switzerland and Amsterdam, The Netherlands, 17 March 2025 - iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, …See details»
iOnctura doses first subject in Phase II UM treatment trial
3 days ago iOnctura co-founder and CEO Catherine Pickering said: “We have achieved our first significant milestone for 2025 by starting one of several planned randomised Phase II studies …See details»
iOnctura Expands Leadership Team with Key Appointments
Mar 17, 2025 The Pioneering Spirit at iOnctura. Both new appointees acknowledged the strategic vision and pioneering spirit at iOnctura. Elizabeth noted her attraction to the …See details»
iOnctura strengthens leadership with appointments of Chief …
Mar 17, 2025 Elizabeth Holt, with a proven track record of forging successful life sciences partnerships, appointed as Chief Business Officer (CBO) Dr Mark Velleca appointed as Board …See details»
iOnctura - Overview, News & Similar companies | ZoomInfo.com
Dec 8, 2023 iOnctura SA, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merck and seed funded by M Ventures. It is a biophar maceutical company …See details»
BioAlps | 20 years of innovation | iOnctura
Mar 7, 2025 The following article is presented to you by iOnctura. Presentation of iOnctura’s activities. iOnctura SA, founded in 2017, is a clinical stage oncology company targeting core …See details»
iOnctura - Raised $112M Funding from 11 investors - Tracxn
6 days ago iOnctura has raised a total funding of $112M over 6 rounds from 11 investors. Investors include EIC Fund, Schroders and 9 others. Their latest funding round was of $85.9M …See details»
iOnctura strengthens leadership team | The Pharmaletter
6 days ago iOnctura is a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, which was established in 2017 as a spin-out from …See details»
How iOnctura is pursuing drug resistance - mednous.com
The iOnctura trial of roginolisib in uveal melanoma is a monotherapy trial giving the company time to study the resistance pathway and the effects of the treatment closely. The upcoming lung …See details»
iOnctura commences randomized Phase II study in metastatic …
3 days ago iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules. The bold new treatments …See details»
iOnctura - Org Chart, Teams, Culture & Jobs - The Org
View iOnctura's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
More documents for XGen Venture (Group) - life-sciences …
IOnctura B.V. Group: iOnctura (Group) Product: XGen Venture Life Science Fund : Product 2: LIFE SCIENCES: Index term: XGen Venture–SEVERAL: investment, 202212–202412 final …See details»
News & views • iOnctura
Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO immuno-oncology congress 2023 . 8 December 2023. Data & publication Safety and clinical efficacy of …See details»